<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-6343</journal-id>
<journal-title><![CDATA[Farmacia Hospitalaria]]></journal-title>
<abbrev-journal-title><![CDATA[Farm Hosp.]]></abbrev-journal-title>
<issn>1130-6343</issn>
<publisher>
<publisher-name><![CDATA[Grupo Aula Médica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-63432020000100006</article-id>
<article-id pub-id-type="doi">10.7399/fh.11333</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Hospital pharmacist's roles and responsibilities with CAR-T medicines]]></article-title>
<article-title xml:lang="es"><![CDATA[Funciones y responsabilidades del farmacéutico de hospital con los medicamentos CAR-T]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Moreno-Martínez]]></surname>
<given-names><![CDATA[María Estela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vinent-Genestar]]></surname>
<given-names><![CDATA[Joan]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Muñoz-Sánchez]]></surname>
<given-names><![CDATA[Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carreras-Soler]]></surname>
<given-names><![CDATA[María Josep]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Santa Creu i Sant Pau Hospital Pharmacy Service ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Sant Joan de Déu Hospital Pharmacy Service ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Catalan Institute of Oncology Pharmacy Service ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Vall d'Hebron University Hospital Pharmacy Service ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2020</year>
</pub-date>
<volume>44</volume>
<numero>1</numero>
<fpage>26</fpage>
<lpage>31</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-63432020000100006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-63432020000100006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-63432020000100006&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract The development and commercialization of cell therapy drugs with chimeric antigen receptor T cells (CAR-T) represent a new challenge for Spain's hospital pharmacy. The aim of this article is to review the key aspects of these medicines and to describe the oncohematological pharmacist's role within the multidisciplinary clinical team. This includes the different phases in the transversal process that involves a therapy with CAR-T medicines, ranging from indication to short and long term follow-up of patients treated with this type of therapy, and emphasizing on the management of its main adverse effects. CAR-T therapy offers the hospital pharmacist the opportunity to work closely with the rest of the clinical professionals involved in the process, allowing their contribution to the development of procedures, clinical practice guidelines of global approach, and establishing starting points when facing future therapies of similar complexity -and even improving previously established basic processes-.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El desarrollo y la comercialización de medicamentos de terapia celular con células T con receptor de antígeno quimérico (CAR-T) suponen un nuevo reto para la farmacia hospitalaria en España. El objetivo de este artículo es revisar los aspectos clave de estos medicamentos y describir el papel del farmacéutico oncohematológico dentro del equipo clínico multidisciplinar en las diferentes fases del proceso transversal que implica el tratamiento con medicamentos CAR-T, desde la indicación hasta el seguimiento a corto y largo plazo de los pacientes tratados con este tipo de terapias, con una importante mención al manejo de sus principales efectos adversos. La terapia tipo CAR-T ofrece al farmacéutico hospitalario la oportunidad de trabajar en estrecha colaboración con el resto de los profesionales clínicos implicados en el proceso, permitiendo su contribución en el desarrollo de procedimientos, guías de práctica clínica de abordaje global y estableciendo puntos de partida para afrontar tratamientos futuros de complejidad similar e incluso mejorar procesos base anteriormente establecidos.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[T-cell chimeric antigen receptor]]></kwd>
<kwd lng="en"><![CDATA[Cytokine release syndrome]]></kwd>
<kwd lng="en"><![CDATA[CAR-T-related encephalopathy syndrome]]></kwd>
<kwd lng="en"><![CDATA[Pharmaceutical care]]></kwd>
<kwd lng="es"><![CDATA[Receptor antigénico quimérico de células T]]></kwd>
<kwd lng="es"><![CDATA[Síndrome de liberación de citoquinas]]></kwd>
<kwd lng="es"><![CDATA[Síndrome de encefalopatía relacionada con CAR-T]]></kwd>
<kwd lng="es"><![CDATA[Atención farmacéutica]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<collab>Spanish Agency of Medicines and Medical Devices</collab>
<collab>Medication Information Center (CIMA)</collab>
<source><![CDATA[Kymriah® data sheet]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Spanish Agency of Medicines and Medical Devices]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="book">
<collab>Spanish Agency of Medicines and Medical Devices</collab>
<collab>Medication Information Center (CIMA)</collab>
<source><![CDATA[Yescarta® data sheet]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Spanish Agency of Medicines and Medical Devices]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Regulation (EC) N. 1394/2007 of the European Parliament and of the Council on November 13, 2007 on advanced therapy medicines]]></article-title>
<source><![CDATA[Official Journal of the European Union]]></source>
<year>2007</year>
<numero>L324</numero>
<issue>L324</issue>
<page-range>121-37</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Directive 2001/83/EC of the European Parliament and of the Council on November 6, 2001 establishing a Community Code on medicinal products for human use]]></article-title>
<source><![CDATA[Official Journal of the European Union]]></source>
<year>2001</year>
<numero>L311</numero>
<issue>L311</issue>
<page-range>61-128</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Regulation (EC) 726/2004 of the European Parliament and of the Council on March 31, 2004, establishing community procedures for the authorization and control of medicinal products for human and veterinary use and establishing the European Medicines Agency]]></article-title>
<source><![CDATA[Official Journal of the European Union]]></source>
<year>2004</year>
<numero>L136</numero>
<issue>L136</issue>
<page-range>1-69</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Royal Legislative Decree 1/2015, of July 24, which approves the consolidated text of the Law on guarantees and rational use of medicines and medical devices]]></article-title>
<source><![CDATA[Official State Gazette]]></source>
<year>2015</year>
<numero>177</numero>
<issue>177</issue>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="">
<collab>Ministry of Health, Consumption and Social Welfare</collab>
<source><![CDATA[Plan de abordaje de las terapias avanzadas en el Sistema Nacional de Salud: medicamentos CAR]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alonso Herreros]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Calleja Hernández]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Carreras Soler]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cordero Cruz]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[García Pellicer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lizeaga Cundin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Procedimiento de gestión de medicamentos CAR-T]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Sociedad Española de Farmacia Hospitalaria]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Black]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacy Institutional Readiness for Marketed CAR-T Therapy: Checklists for Pharmacy Services]]></source>
<year>2018</year>
<publisher-name><![CDATA[Specialist Pharmacy Service]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistical and Toxicity Management Practices in the United States]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahmourdjafari]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Hawks]]></surname>
<given-names><![CDATA[KG]]></given-names>
</name>
<name>
<surname><![CDATA[Hsieh]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Piesca]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gatwood]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Culos]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
</person-group>
<source><![CDATA[Biol Blood Marrow Transplant]]></source>
<year>2019</year>
<volume>25</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>26-33</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities and Recommendations from the ASBMT Pharmacy Special Interest Group]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clemmons]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[DeGregory]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kennedy]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Biol Blood Marrow Transplant]]></source>
<year>2018</year>
<volume>24</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>914-22</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="book">
<collab>Dirección General de Cartera Básica de Servicios del SNS y Farmacia</collab>
<source><![CDATA[Criterios y estándares designación de centros CAR-T]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Sanidad, Consumo y Bienestar Social]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="book">
<collab>Dirección General de Cartera Básica de Servicios del SNS y Farmacia</collab>
<source><![CDATA[Protocolo farmacoclínico del uso de tisagenlecleucel en linfoma B difuso de células grandes en el Sistema Nacional de Salud]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Sanidad, Consumo y Bienestar Social]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="book">
<collab>Dirección General de Cartera Básica de Servicios del SNS y Farmacia</collab>
<source><![CDATA[Protocolo farmacoclínico del uso de tisagenlecleucel en la leucemia linfoblastica aguda de células B en el Sistema Nacional de Salud]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Sanidad, Consumo y Bienestar Social]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="book">
<collab>Dirección General de Cartera Básica de Servicios del SNS y Farmacia</collab>
<source><![CDATA[Protocolo clínico para el manejo de los efectos adversos graves en pacientes tratados con medicamentos que contienen células T CAR (Chimeric Antigen Receptor) anti-CD 19 (CART-19)]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Sanidad, Consumo y Bienestar Social]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="book">
<collab>London Medicines Information Service</collab>
<source><![CDATA[Evidence for use of siltuximab or anakinra as second line therapies (after failure of tocilizumab) for Cytokine Release Syndrome (CRS) following use of Chimeric Antigen Receptor T-cell (CAR- T) therapy]]></source>
<year>2019</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[National Health Service]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
